Tiaprofenic acid is a non-steroidal anti-inflammatory drug that is used in the treatment of patients with sprains, muscle pains, joint pains, and arthritis (rheumatoid and osteoarthritis).
Tiaprofenic acid Uses:
Note: The drug is not yet approved for use in the USA
-
Osteoarthritis:
- Helps in alleviation of signs and symptoms in patients with osteoarthritis
-
Rheumatoid arthritis:
- Helps in alleviation of signs and symptoms of rheumatoid arthritis
Tiaprofenic acid Dose in Adults
Tiaprofenic acid Dose in the treatment of Osteoarthritis: Oral:
Usual initial and maintenance dose: 600 mg/day divided in 2 to 3 doses; rarely, patients may be given a maintenance dose of 300 mg/day in divided doses; The maximum dose: 600 mg/day
Tiaprofenic acid Dose in the treatment of Rheumatoid arthritis: Oral:
The typical initial and maintenance dose is 600 mg/day divided into two to three doses; the daily maximum is 600 mg.
Use in Children:
Not indicated.
Pregnancy Risk Category: C
- Several adverse effects on animal reproduction were discovered during the study of the drug.
- These included an increase in stillbirths and delayed or prolonged labor.
- Tiaprofenic Acid can cross the human placental boundary.
- NSAID use during late pregnancy is linked to a high risk of ductus arteriosis premature closure in the foetus.
- Although the association between congenital anomalies or malformations and NSAID use in the first trimester has not been strong, there are some studies that have shown a link between NSAID and cardiovascular anomalies.
- The use of NSAIDs close to conception may increase the risk of miscarriage.
Non-teratogenic consequences include cardiac degenerative changes, renal dysfunction or failure, oligohydramnios, prenatal ductus arteriosus constriction or rupture, foetal prenatal constriction or regurgitation, failure to seal the ductus arteriosus postnatally. - Late-pregnancy NSAID use is discouraged by certain medical professionals because it increases the risk of premature ductus arteriosis closure.
- Using NSAIDs for a prolonged period of time by women who are pregnant may cause infertility. However, this can be reversed once the medication is stopped.
- Pregnancy is not a good time to use tiaprofenic acids.
Use during breastfeeding:
- It is unknown if tiaprofenic acids is found in breast milk. The manufacturer does not recommend breast-feeding.
Dose in Kidney Disease:
- There are no specific dosage adjustments for renal dysfunction patients given in the manufacturer’s labeling.
- However, dosage adjustment is recommended as tiaprofenic acid is primarily eliminated by kidneys.
Dose in Liver disease:
- There are no dosage adjustments provided in the manufacturer’s labeling.
- Use with caution.
Common Side Effects of Tiaprofenic acid:
-
Gastrointestinal:
- Dyspepsia
Less Common Side Effects of Tiaprofenic acid:
-
Cardiovascular:
- Edema
- Flushing
-
Central Nervous System:
- Dizziness
- Headache
- Drowsiness
- Depression
-
Dermatologic:
- Erythema
- Pruritus
- Skin Rash
-
Endocrine & Metabolic:
- Hyperkalemia
-
Gastrointestinal:
- Nausea
- Heartburn
- Epigastric Pain
- Vomiting
- Constipation
- Abdominal Pain
- Diarrhea
- Flatulence
- Stomatitis
- Xerostomia
-
Hematologic & Oncologic:
- Decreased Hematocrit
- Decreased Hemoglobin
-
Renal:
- Increased Blood Urea Nitrogen
-
Respiratory:
- Epistaxis
Contraindications to Tiaprofenic acid:
- Hypersensitivity to tiaprofenic acids, any component of this formulation, aspirin or other non-steroidal anti-inflammatory drug (NSAIDs)
- Patients with acute asthma attacks, urticaria or rhinitis who have received aspirin or NSAID therapy for their allergic manifestations;
- Active gastrointestinal inflammatory diseases or peptic ulcer disease
Warnings and precautions
-
Anaphylactoid reactions
- Asthmatic and anaphylactic reactions have been fatal in patients with the "aspirin trifecta" (asthma, sinus inflammation, recurrent nose polyps, and sensitivity to aspirin or other NSAIDs).
-
Aseptic meningitis
- Aseptic meningitis can be rare with some NSAIDS, especially for patients with autoimmune diseases.
-
Cardiovascular events
- There is a high risk of developing serious cardiovascular complications such as myocardial injury, CVA, or new-onset hypertension.
- A longer use duration or pre-existing heart disease or cardiovascular risk factors may increase the risk.
- Before prescribing NSAIDs, every patient should have their cardiovascular condition evaluated.
- Fluid retention should be handled with caution
- In heart failure, should not be used.
- To reduce cardiovascular events, use the lowest effective dose for the most time. High-risk patients should receive alternate treatments.
-
CNS effects
- This may cause blurred vision, drowsiness, blurred vision, or other neurologic effects that can lead to impairment of either physical or mental capabilities.
- Patients should be cautious about tasks that require mental alertness such as operating machinery or driving.
-
Cystitis
- NSAIDs have been used to treat severe cases of cystitis (bladder pains, dysurias, urinary frequency, hematuria), which can include bladder pains, dysurias, bladder pains, and urinary frequency.
- Patients with a history of urinary symptoms should not use this medication.
- Stop using it immediately if you experience any genitourinary problems.
-
Events involving the GI
- Sometimes, bleeding from the stomach may not be accompanied by symptoms of GI irritation.
- Contraindicated for active GI inflammatory diseases and peptic ulcer disease.
- Suspected/confirmed peptic Ulcer, GI bleeding, or perforation are reasons to stop using this medication.
- Avoid non-aspirin NSAIDs in patients who have had a history or experience of severe lower GI bleeding.
- Those who have a history of gastrointestinal disorders (bleeding, ulcers, or past GI symptoms with NSAID usage, concomitant therapy with aspirin, anticoagulants, and/or corticosteroids, smoking, alcohol use, the elderly, or debilitated individuals) are advised to use this medication with caution.
- Concomitant use of =325mg of aspirin can lead to a significant increase in the risk for GI complications (eg ulcers).
- Therefore, it is recommended that patients receiving these medications be given concomitantly (eg, proton pumps inhibitors, Bhatt, 2008).
-
Hematologic effects
- It decreases platelet adhesion, aggregation and prolongs bleeding time.
- Anemia can occur. Patients on long-term NSAID therapy need to be closely monitored.
- Rarely is there a connection with potentially severe blood disorders (eg, anemia, thrombocytopenia and agranulocytosis).
-
Hyperkalemia:
- NSAIDs may increase hyperkalemia risk, especially in elderly people, diabetics, and those who use concomitantly with ACE-inhibitors.
- These patients should be monitored closely for potassium.
-
Ocular effects
- This medication can cause blurred vision or decreased vision.
- All patients receiving long-term therapy should have their vision regularly evaluated
-
Reactions to skin:
- NSAIDs can cause severe adverse skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis. Stop using NSAIDs immediately if you experience skin rash or hypersensitivity.
-
Asthma
- Patients with asthma should not use it as it can cause severe bronchospasm.
-
Hepatic impairment
- Patients with reduced hepatic function should be cautious.
- It is important to monitor the function of your liver
- Rarely, the usage of this medicine has been linked to serious liver responses (such jaundice or deadly hepatitis).
- Stop using it if you experience any symptoms or indicators of liver disease or other systemic manifestations.
- With prolonged use, monitor LFT frequently.
-
Hypertension:
- Usage with caution since it could lead to the emergence of new hypertension or exacerbate existing hypertension
-
Renal impairment
- NSAIDs can cause impairment of renal function. A dose-dependent decrease is possible in prostaglandin synthesis.
- Patients with impaired renal function, heart disease, liver dysfunction, heart failure, or dehydration, as well as those who take diuretics and ACE inhibitors, are more at risk for renal toxicity.
- It is a good idea to hydrate the patient before you start the therapy
- It is important to reduce your dose and monitor your renal function.
- Long-term NSAID treatment may cause renal papillary necrosis.
Tiaprofenic acid (United States: Not available): Drug Interaction
|
5-Aminosalicylic Acid Derivatives |
Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. |
|
Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.) |
May enhance the antiplatelet effect of other Agents with Antiplatelet Properties. |
|
Alcohol (Ethyl) |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination. |
|
Aliskiren |
Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent. Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction. |
|
Aminoglycosides |
Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. |
|
Aminolevulinic Acid (Topical) |
Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). |
|
Angiotensin II Receptor Blockers |
May enhance the adverse/toxic effect of Nonsteroidal AntiInflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function. |
|
Angiotensin-Converting Enzyme Inhibitors |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. |
|
Anticoagulants |
Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. Exceptions: Bemiparin; Enoxaparin; Heparin. |
|
Anticoagulants |
Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants. Exceptions: Bemiparin; Enoxaparin; Heparin. |
|
Beta-Blockers |
|
|
Bisphosphonate Derivatives |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. |
|
Cephalothin |
Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. |
|
Collagenase (Systemic) |
Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. |
|
Corticosteroids (Systemic) |
May enhance the adverse/toxic effect of Nonsteroidal AntiInflammatory Agents (Nonselective). |
|
Dasatinib |
May enhance the anticoagulant effect of Agents with Antiplatelet Properties. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. |
|
Deferasirox |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. |
|
Deoxycholic Acid |
Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. |
|
Desmopressin |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin. |
|
Digoxin |
Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. |
|
Drospirenone |
Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Drospirenone. |
|
Eplerenone |
Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. |
|
Fat Emulsion (Fish Oil Based) |
May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. |
|
Felbinac |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Glucosamine |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Haloperidol |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion. |
|
HydrALAZINE |
Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. |
|
Ibritumomab Tiuxetan |
Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. |
|
Ibrutinib |
May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. |
|
Inotersen |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Limaprost |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Multivitamins/Fluoride (with ADE) |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Multivitamins/Minerals (with ADEK, Folate, Iron) |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Multivitamins/Minerals (with AE, No Iron) |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Naftazone |
May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Obinutuzumab |
Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. |
|
Omega-3 Fatty Acids |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Pentosan Polysulfate Sodium |
May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents. |
|
Pentoxifylline |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Porfimer |
Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. |
|
Potassium-Sparing Diuretics |
Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. |
|
PRALAtrexate |
Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate. Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation. |
|
Probenecid |
May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. |
|
Prostacyclin Analogues |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Prostaglandins (Ophthalmic) |
Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). |
|
Quinolones |
Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. |
|
Salicylates |
Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. |
|
Serotonin/Norepinephrine Reuptake Inhibitors |
May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). |
|
Tacrolimus (Systemic) |
Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). |
|
Thiazide and Thiazide-Like Diuretics |
May enhance the nephrotoxic effect of Nonsteroidal AntiInflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics. |
|
Thrombolytic Agents |
Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. |
|
Tipranavir |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Tolperisone |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Tricyclic Antidepressants (Tertiary Amine) |
May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). |
|
Vancomycin |
Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. |
|
Verteporfin |
Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. |
|
Vitamin E (Systemic) |
May enhance the antiplatelet effect of Agents with Antiplatelet Properties. |
|
Risk Factor D (Consider therapy modification) |
|
|
Apixaban |
Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. |
|
Bemiparin |
Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding. |
|
Bemiparin |
Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding. |
|
Bile Acid Sequestrants |
May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. |
|
CycloSPORINE (Systemic) |
Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs). Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs. |
|
Dabigatran Etexilate |
Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. |
|
Diclofenac (Systemic) |
|
|
Edoxaban |
Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. |
|
Enoxaparin |
Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Enoxaparin. Management: Discontinue nonsteroidal anti-inflammatory agents (NSAIDs) prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding. |
|
Enoxaparin |
Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin. Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding. |
|
Heparin |
Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required. |
|
Heparin |
Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required. |
|
Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry) |
May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur. Management: Avoid combination when possible. If used, monitor more closely for evidence of bleeding. Discontinue herbal products with anticoagulant or antiplatelet actions 2 weeks prior to surgical, dental, or invasive procedures. |
|
Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry) |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed. |
|
Lithium |
Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium. |
|
Loop Diuretics |
Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended. |
|
Methotrexate |
Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate. Management: Alternative anti-inflammatory therapy should be considered whenever possible, especially if the patient is receiving higher, antineoplastic doses of methotrexate. |
|
Rivaroxaban |
Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding. |
|
Salicylates |
Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Exceptions: Choline Magnesium Trisalicylate. |
|
Selective Serotonin Reuptake Inhibitors |
May enhance the antiplatelet effect of Nonsteroidal AntiInflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk. |
|
Sincalide |
Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. |
|
Sodium Phosphates |
May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely. |
|
Tenofovir Products |
Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose. |
|
Vitamin K Antagonists (eg, warfarin) |
Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists. |
|
Risk Factor X (Avoid combination) |
|
|
Acemetacin |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Aminolevulinic Acid (Systemic) |
Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). |
|
Dexibuprofen |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Dexibuprofen. |
|
Dexketoprofen |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Floctafenine |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Ketorolac (Nasal) |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Ketorolac (Systemic) |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Macimorelin |
Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. |
|
Mifamurtide |
Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. |
|
Morniflumate |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). |
|
Omacetaxine |
Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL. |
|
Pelubiprofen |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Phenylbutazone: |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Talniflumate |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Tenoxicam |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
|
Urokinase |
Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. |
|
Zaltoprofen |
May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. |
Monitoring parameters:
- CBC;
- occult blood loss;
- periodic liver function tests; renal function (urine output, BUN, creatinine); electrolytes;
- monitor response (pain, range of motion, grip strength, mobility, ADL function), inflammation;
- observe for weight gain, edema;
- observe for bleeding, bruising;
- evaluate gastrointestinal effects (abdominal pain, bleeding, dyspepsia);
- mental confusion, disorientation;
- periodic ophthalmic exams
How to administer Tiaprofenic acid?
- Administer with food or milk.
Mechanism of action of Tiaprofenic acid:
- It inhibits cyclooxygenase-1 (COX-1) and 2 enzymes in a way that is reversible.
- This results in decreased production of prostaglandin precursors.
- The inhibition of chemotaxis, modification of lymphocyte activity, inhibition of neutrophil aggregation/activation, and a decrease in proinflammatory cytokine levels are additional proposed mechanisms that have not yet been fully elucidated but may contribute to the anti-inflammatory effect to varying degrees.
Absorption: Rapid (delayed by food)
Protein binding: ~98%
Metabolism: Minimal (10%) to inactive metabolites
Half-life elimination: ~2 hours
Time to peak: 30 to 90 minutes (delayed ~10% by food)
Excretion: Urine (50% as unchanged drug; <10% as metabolites)
International Brand Names of Tiaprofenic acid:
- PO-Tiaprofenic
- DOM-Tiaprofenic Acid
- PMS-Tiaprofenic
- Surgam
- TEVA-Tiaprofenic Acid
- Artiflam
- Fengam
- Pain Will Pass
- Rakotamil
- Sufen
- Surgam
- Surgam SR
- Surgamyl
- Torpas
- Trobenide
Tiaprofenic acid Brand Names in Pakistan:
No Brands Available in Pakistan.
 Injection for familial chylomicronemia syndrome.jpeg)
